Press & Media Kit

talavo is a free iOS browser that strips the attention-engineered UI out of the modern web, YouTube ads, Shorts, comments, and community posts, leaving only the content you came for. Built by an independent two-person studio. No browsing data collected.

talavo is a free, distraction-free web browser for iPhone and iPad. It removes YouTube ads, Shorts, comments, and community posts at the browser level, and adds a mini-player and picture-in-picture so video keeps playing while you browse other sites, without a YouTube Premium subscription. talavo collects no browsing data; settings, bookmarks, and history stay on the device. It is built and run full-time by a self-funded two-person studio that takes no investor money. The core app is free; the optional talavo Pro ($0.99/month) removes a single launch ad and adds Split Screen, Corner Player, and Zen+.

talavo is a free, distraction-free web browser for iPhone and iPad, built for people who want the web without its attention traps. Instead of relying on willpower or paid subscriptions, talavo removes the entry points to the dopamine loops at the browser level: YouTube ads, Shorts, comments, and community posts disappear, Instagram Reels can be hidden too, and general web ads are filtered through Apple's native WKContentRuleListStore. A mini-player keeps video playing while you switch sites, picture-in-picture works without YouTube Premium, and audio continues in the background or with the screen locked. talavo is structurally private: no talavo server observes the URLs you visit, and settings, bookmarks, and history stay on the device. The studio behind it is an independent, self-funded team of two, founded in 2024 and working full-time since 2025, with no investors and no acquisition pitch. The core app is free, with one brief ad when it launches. talavo Pro, at $0.99/month or $9.99/year, removes that ad and adds Split Screen, a Corner Player, Zen+ for hiding any page element, Shortcut Locks, and dark themes. Every install starts with a 14-day Pro trial.